The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one ...

Oric Pharmaceuticals ( ($ORIC) ) has provided an announcement. On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market ...

One-third (1/3rd) of the restricted stock units will vest ... stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.

ORIC-944: a potent and selective allosteric inhibitor ... For the year ended December 31, 2024, R&D expenses were $114.1 million compared to $85.2 million for the same period in 2023, an increase ...

ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer ...